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1. Pathology of the pleura
Pleural disorders are always in the shadow of lung diseases. The discussion of 
these diseases has been neglected in relation to other diseases although the symp-
toms of pleural effusion always accompany lung as well as heart diseases.
Inflammation of the pleura may be acute or chronic, of nonspecific or specific 
type. Prolonged, chronic effusion causes reactive changes on mesothelial cells that 
can be histologically misdiagnosed as malignancy. Tuberculosis inflammation 
causes pleural effusion characterized by the presence of large numbers of lympho-
cytes and a small number of mesothelial cells. Tuberculous pleuritis is the most 
common form of extrapulmonary tuberculosis [1].
Malignant pleural effusions are a consequence of lung cancer spreading to 
visceral or parietal pleura. Pleural mesothelioma also causes effusions [2, 3].
The most accurate differential diagnosis between primary lung cancer and 
pleural mesothelioma is immunohistochemical diagnosis [4–7].
Pleural tumors originate from mesenchymal cells of the epithelial type and 
submesothelial cells of the mesenchymal type. The most common pleural mesen-
chymal tumor is a solitary fibrous tumor of the pleura. The biological behavior of 
this tumor of the pleura is predicted by the proliferation marker, protein Ki-67, 
and when its index is more than 4 mitoses at 2 mm2 or >4/10 high power fields, 
it may be considered as a malignant alteration that creates dilemmas about the 
treatment [8, 9].
We will pay particular attention to reactive mesothelial cells as well as to tumors 
of the pleura.
Figure 1. 
Cellular pleural effusion with mass of reactive mesothelial cells.
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Reactively altered mesothelial cells are difficult to distinguish morphologically 
from malignant mesothelial cells both on biopsy and on effusion (Figure 1) [8, 9]. 
Recently, a monoclonal antibody, bap-1, which is mainly expressed in reactive 
mesothelial cells has been used (Figure 2). It is also expressed in malignant meso-
thelial cells but not in malignant cells of another origin, such as lung adenocarci-
noma [10].
According to the latest WHO classification of pleural tumors [8], they are 
divided into mesothelial tumors, mesenchymal tumors, and lymphoproliferative 
disorders.
2. Classification of pleural tumors
• Mesothelial tumors
 ○ Diffuse malignant mesothelioma
 ○ Epithelioid mesothelioma
 ○ Sarcomatoid mesothelioma
 ○ Biphasic mesothelioma
 ○ Desmoplastic mesothelioma
 ○ Localized malignant mesothelioma
 ○ Other tumors of mesothelial origin
 ○Well-differentiated papillary mesothelioma
 ○ Adenomatoid tumor
Figure 2. 
Bap-1 is a protein expressed in reactive mesothelial cells.
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• Lymphoproliferative disorders
 ○ Primary effusion lymphoma
 ○ Pyothorax—associated with lymphoma
• Mesenchymal tumors
 ○ Epithelioid hemangioendothelioma
 ○ Angiosarcoma
 ○ Synovial sarcoma
 ○Monophasic
 ○ Biphasic
 ○ Solitary fibrous tumor
 ○ Calcifying tumor of pleura
 ○ Desmoplastic round cell tumor
We will consider the most common types, in the group of mesothelial tumors—pleu-
ral mesothelioma and in the group of mesenchymal tumors—solitary fibrous tumor.
Pleural mesothelioma is divided into the most common, monophasic, epitheli-
oid type (Figure 3); sarcomatoid type (Figure 4); biphasic, epithelioid/sarcoma-
toid (Figure 5) and the rarest, difficult-to-diagnose, desmoplastic type (Figure 6). 
Epithelioid mesothelioma is diagnosed and differentiated from carcinoma that 
involve pleura with monoclonal antibodies: podoplanin (D2-40) (Figure 7), 
HBME-1 (Figure 8), cytokeratin 5 (Figure 9), calretinin (Figure 10), and WT-1 
(Figure 11). By using several of these antibodies, epithelioid mesothelioma can be 
diagnosed with great certainty. Sarcomatoid mesothelioma can be diagnosed by 
using the following antibodies: cytokeratin, vimentin, HBME-1, and Fascin, but 
this type can be differentiated from pulmonary sarcomatoid carcinoma only by 
clinical findings [4–8].
Figure 3. 
The most frequent type is epithelioid malignant mesothelioma.
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Figure 6. 
Desmoplastic malignant mesothelioma is a rare type and difficult for pathological diagnosis.
Figure 5. 
Sarcomatoid type of malignant mesothelioma.
Figure 4. 
Mixed, epithelioid/sarcomatoid type of malignant mesothelioma.
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Figure 7. 
Podoplanin (D2-40) is characteristic antibody for diagnosis of epithelioid type of malignant mesothelioma.
Figure 8. 
HBME-1 is useful antibody for diagnosis of epithelioid type of malignant mesothelioma.
Figure 9. 
Cytokeratin 5 is dominant antibody for diagnosis of epithelioid type of malignant mesothelioma.
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Solitary fibrous tumor is fibroblastic neoplasm, consisting of primitive 
connective tissue cells, which can therefore mimic morphological picture 
of neurofibroma or hemangiopericytoma with zones of hypercellularity 
(Figure 12) and hypocellularity (Figure 13). However, solitary fibrous tumor is 
characterized by immunophenotype of tumor cells. These cells express vimen-
tin, CD34, bcl-2, and Stat-6 (Figure 14). The proliferation index of these cells 
is low in benign phase, less than 2 mitosis/10 HPF (Figure 15). If this tumor 
recurs and proliferation index is elevated, it is advised that tumor is treated as a 
sarcoma [11, 12].
Rare mesenchymal tumors are epithelioid hemangioendotheliomas which can 
be bilateral, both in the lungs and in the pleura. Monophasic and biphasic types of 
synovial sarcoma are also rare. These tumors have a specific immunophenotype, 
where epithelioid hemangioendothelioma (Figures 16–18) expresses vascular 
markers, while synovial sarcoma expresses (Figures 19 and 20) itself as synovial 
sarcoma of the joints but with a specific genetic mutation [13–15].
Figure 11. 
WT-1 is dominant antibody for diagnosis of epithelioid type of malignant mesothelioma.
Figure 10. 
Calretinin is useful for diagnosis of epithelioid type of malignant mesothelioma but could be expressed in lung 
adenocarcinoma.
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Figure 12. 
Hypercellular zone of solitary fibrous tumor of pleura.
Figure 13. 
Hypocellular zone of solitary fibrous tumor of pleura.
Figure 14. 
Stat-6 is a characteristic antibody for diagnosis of solitary fibrous tumor of pleura.
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Figure 17. 
Fli-1 expression in cells confirmed endothelial cells.
Figure 16. 
Small cleft covered focally by with “signet ring cell” appearance in epithelioid hemangioendothelioma.
Figure 15. 
High Ki-67 proliferative index (>4/10 high power fields), is a sign of malignant alteration of solitary fibrous 
tumor of pleura.
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Figure 18. 
ERG expression also confirmed endothelial origin of the tumor cells.
Figure 19. 
Small spindle cells in sarcomatoid type of synoviosarcoma.
Figure 20. 
Tle-1 is expressed in synoviosarcoma.
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